02772nam a2200241   4500001000700000090001100007100004100018101000800059200017300067210007900240215002000319300014500339330170600484606003002190606003502220606002702255606002402282700003302306701002602339701003602365955001102401995011802412393394  a393394  a20150721d2013       y0pory50      ba  aeng  aComprehensive forensic toxicological analysis of designer drugsbRecurso eletrónicoefinal technical reportfAnthony P. DeCaprio, W. Lee Hearn, Madeleine J. Swortwood  a[Rockville, MD]cNational Criminal Justice Reference Service (NCJRS)d2013  a1 CD-ROMd12 cm  aResearch report submitted to the U.S. National Institute of Justice, Office of Justice Programs. Ficheiro de 1,61 MB em formato PDF (53 p.).  a«"Designer drugs" are analogs or derivatives of controlled substances that are sold on the street in an attempt to circumvent the legal restrictions placed on scheduled drugs. New designer drugs are constantly emerging onto the illicit drug market and it is often difficult to validate and maintain comprehensive analytical methods for accurate detection of these compounds. Chemical modifications in these substances can be very subtle, leading to virtually unlimited structural variation. As a consequence, there are many hundreds of such entities that have been identified to date. Generally, forensic toxicology labs utilize a screening method, such as immunoassay, for the presumptive identification of drugs of abuse. When a positive result occurs, confirmatory methods, such as gas chromatography (GC) or liquid chromatography (LC) coupled with mass spectrometry (MS), are required for more sensitive and specific qualitative and quantitative analyses. In recent years, the need to study the activities of these compounds in screening assays as well as to develop confirmatory techniques to detect them in biological specimens has been recognized. Designer drugs have been a major topic of concern in Europe for some time and this issue has also become increasingly important in the United States. (…). The present project included two primary tasks. Task 1 consisted of determination of the cross-reactivity of designer drugs in common commercially available immunoassays. Task 2 consisted of similar screening evaluation using a series of blind spiked serum samples, with comparison to screening results obtained using a validated LC-QQQ-MS method and highresolution LC-QTOF-MS analysis.»  aDROGA SINTÉTICA9320915  aANÁLISE LABORATORIAL9326721  aESTUPEFACIENTE9343050  aTOXICOLOGIA9263124  aDECAPRIObAnthony P.9357798  aHEARNbW. Lee9114086  aSWORTWOODbMadeleine J.9357799  xOferta  104PJCD_258_00000000000000052022-06-066PJCD2589425841aPJcPJfPJ1CD258_57kPJCD258n2022-06-06o0rMOxOferta